"Pharmacoepidemiology" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
Descriptor ID |
D017891
|
MeSH Number(s) |
H01.158.703.045 H02.403.720.500.650 H02.628.413
|
Concept/Terms |
Pharmacoepidemiology- Pharmacoepidemiology
- Pharmaceutical Epidemiology
- Epidemiologies, Pharmaceutical
- Pharmaceutical Epidemiologies
- Epidemiology, Pharmaceutical
|
Below are MeSH descriptors whose meaning is more general than "Pharmacoepidemiology".
Below are MeSH descriptors whose meaning is more specific than "Pharmacoepidemiology".
This graph shows the total number of publications written about "Pharmacoepidemiology" by people in this website by year, and whether "Pharmacoepidemiology" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 5 | 3 | 8 |
2018 | 4 | 1 | 5 |
2019 | 0 | 2 | 2 |
2020 | 1 | 0 | 1 |
2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacoepidemiology" by people in Profiles.
-
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. Am J Epidemiol. 2021 11 02; 190(11):2405-2419.
-
Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects. Therapie. 2021 Jul-Aug; 76(4):305-309.
-
Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety. Pharmacoepidemiol Drug Saf. 2021 07; 30(7):843-857.
-
The Use of Primary Care Big Data in Understanding the Pharmacoepidemiology of COVID-19: A Consensus Statement From the COVID-19 Primary Care Database Consortium. Ann Fam Med. 2021 Mar-Apr; 19(2):135-140.
-
Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. Basic Clin Pharmacol Toxicol. 2021 05; 128(5):649-651.
-
Ways COVID-19 may impact unrelated pharmacoepidemiologic research using routinely collected data. Pharmacoepidemiol Drug Saf. 2021 03; 30(3):400-401.
-
Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020 12; 43(12):1205-1210.
-
Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020 08; 29(8):825-831.
-
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Res Social Adm Pharm. 2021 01; 17(1):2012-2017.
-
Clopidogrel Drug Interactions and Serious Bleeding: Generating Real-World Evidence via Automated High-Throughput Pharmacoepidemiologic Screening. Clin Pharmacol Ther. 2019 11; 106(5):1067-1075.